CONTROLLED RELEASE FORMULATIONS USING INTELLIGENT POLYMERS
A controlled release pharmaceutical composition comprises (a) topiramate or a pharmaceutically acceptable salt thereof, (b) a first intelligent polymer component; and (c) a second intelligent polymer component having opposite wettability characteristics to the first intelligent polymer component. The polymer components are effective for controlled release of the pharmaceutically active substance from the composition.
1 . A controlled release matrix tablet comprising:
(a) topiramate or a pharmaceutically acceptable salt thereof;
(b) a first intelligent polymer component; and
(c) a second intelligent polymer component having opposite wettability characteristics to said first intelligent polymer component;
wherein the first intelligent polymer component is more hydrophobic than the second intelligent polymer component; and wherein the first and second intelligent polymer components constitute a substantially homogeneous matrix, wherein the topiramate or pharmaceutically acceptable salt thereof is substantially homogeneously dispersed in the substantially homogeneous matrix.
2 . The controlled release matrix tablet of claim 1 , wherein the first and second intelligent polymers have the following single and three-component solubility parameters (MPa 0.5 ) calculated using the group contribution method:
δ
δ t
δ d
δ p
δ h
δ −a
First intelligent polymer
15-25
14-24
12-17
2-7
5-15
6-13
Second intelligent polymer
18-50
18-45
12-17
2-8
12-20
13-20
wherein δ is the conventional Hildebrand parameter, t=total, d=dispersion, p=polar, h=hydrogen bond and a=association interactions.
3 . The controlled release matrix tablet of claim 1 , wherein the first intelligent polymer component is present in an amount of not less than about 5% by weight.
4 . The controlled release matrix tablet of claim 1 wherein the first intelligent polymer component is ethylcellulose.
5 . The controlled release matrix tablet of claim 1 wherein the second intelligent polymer component is present in an amount of from about 15% to about 50% by weight.
6 . The controlled release matrix tablet of claim 1 wherein the second intelligent polymer component is a mixture of hydroxyethylcellulose and hydroxypropylmethylcellulose.
7 . The controlled release matrix tablet of claim 1 further comprising at least one pharmaceutically acceptable excipient.
8 . The controlled release matrix tablet of claim 1 , wherein the composition further comprises about 10% to about 70% by weight of at least one channeling agent.
9 . The controlled release matrix tablet of claim 8 , wherein the at least one channeling agent is lactose.
10 . The controlled release matrix tablet of claim 1 , wherein the composition further comprises about 0.1% to about 5% by weight of at least one lubricant.
11 . The controlled release matrix tablet of claim 10 , wherein the at least one lubricant is magnesium stearate.
12 . The controlled release matrix tablet of claim 1 , wherein said controlled release matrix tablet further comprises about 0.25% to about 5% by weight of at least one glidant.
13 . The controlled release matrix tablet of claim 12 , wherein the glidant is silicon dioxide.
14 . The controlled release matrix tablet of claim 1 wherein said controlled release matrix tablet further comprises up to about 15% by weight of at least one surface active agent.
15 . The controlled release matrix tablet of claim 14 , wherein said surface active agent is a block copolymer of polyoxyethylene and polyoxypropylene.
16 . The controlled release matrix tablet of claim 1 wherein said controlled release matrix tablet is free of a surface active agent.
17 . The controlled release matrix tablet of claim 1 , wherein said controlled release matrix tablet further comprises about 5% to about 30% of at least one compression enhancer.
18 . The controlled release matrix tablet of claim 17 , wherein said compression enhancer is microcrystalline cellulose.
19 . The controlled release matrix tablet of claim 1 comprising:
(a) from about 0.5% to about 70% by weight of topiramate or a pharmaceutically acceptable salt thereof;
(b) not less than about 5% by weight ethylcellulose; and
(c) from about 15% to about 50% by weight of a mixture of hydroxyethylcellulose and hydroxypropylmethylcellulose, wherein the ratio of hydroxyethylcellulose to hydroxypropylmethylcellulose is from about 1:100 to about 100:1.
20 . The controlled release matrix tablet of claim 1 comprising:
(a) about 50% by weight of topiramate or a pharmaceutically acceptable salt thereof;
(b) about 5% by weight of ethylcellulose;
(c) about 3.5% by weight of hydroxyethylcellulose and about 15% by weight of hydroxypropylmethylcellulose.
21 . The controlled release matrix tablet of claim 1 wherein the tablet is uncoated.
22 . The controlled release matrix tablet of claim 1 wherein the tablet is coated with one or more coats.
23 . The controlled release matrix tablet of claim 22 wherein the tablet is coated with a coating composition which undergoes gradual dissolution in the gastrointestinal (GI) system.
24 . The controlled release matrix tablet of claim 23 wherein the coating composition which undergoes gradual dissolution in the gastrointestinal (GI) system comprises an anionic copolymer of methacrylic acid and methyl methacrylate.
25 . A controlled release matrix tablet comprising topiramate or a pharmaceutically acceptable salt thereof wherein the tablet is bioequivalent to a reference formulation of topiramate or a pharmaceutically acceptable salt thereof.
26 . A controlled release matrix tablet comprising topiramate or a pharmaceutically acceptable salt thereof wherein the tablet exhibits an in vitro/in vivo correlation.
27 . A controlled release matrix tablet comprising topiramate or a pharmaceutically acceptable salt thereof wherein the tablet exhibits a dissolution profile at pH 6.8 or at 4.5 such that after about 1 hour, no more than about 15% of the topiramate or pharmaceutically acceptable salt thereof is released; after about 2 hours, from about 5% to about 35% of the topiramate or pharmaceutically acceptable salt thereof is released; after about 4 hours, from about 20% to about 60% of the topiramate or pharmaceutically acceptable salt thereof is released; after about 8 hours, from about 35% to about 95% of the topiramate or pharmaceutically acceptable salt thereof is released; after about 12 hours, no less than about 50% of the topiramate or pharmaceutically acceptable salt thereof is released; and after about 16 hours, no less than about 60% of the topiramate or pharmaceutically acceptable salt thereof is released.
28 . The controlled release matrix tablet of claim 27 wherein the tablet exhibits a dissolution profile at pH 6.8 such that after about 1 hour, no more than about 15% of the topiramate or pharmaceutically acceptable salt thereof is released; after about 2 hours, from about 15% to about 35% of the topiramate or pharmaceutically acceptable salt thereof is released; after about 4 hours, from about 30% to about 60% of the topiramate or pharmaceutically acceptable salt thereof is released; after about 8 hours, from about 55% to about 90% of the topiramate or pharmaceutically acceptable salt thereof is released; after about 12 hours, no less than about 75% of the topiramate or pharmaceutically acceptable salt thereof is released; and after about 16 hours, no less than about 85% of the topiramate or pharmaceutically acceptable salt thereof is released.
29 . The controlled release matrix tablet of claim 27 wherein the tablet exhibits a dissolution profile at pH 4.5 such that after about 1 hour, no more than about 15% of the topiramate or pharmaceutically acceptable salt thereof is released; after about 2 hours, from about 20% to about 30% of the topiramate or pharmaceutically acceptable salt thereof is released; after about 4 hours, from about 40% to about 60% of the topiramate or pharmaceutically acceptable salt thereof is released; after about 8 hours, from about 65% to about 95% of the topiramate or pharmaceutically acceptable salt thereof is released; and after about 12 hours, no less than about 90% of the topiramate or pharmaceutically acceptable salt thereof is released.
30 . A method of treating seizures in a patient in need thereof, the method comprising administering the controlled release tablet of claim 1 to the patient.
31 . A method of treating or preventing migraine in a patient in need thereof, the method comprising administering the controlled release tablet of claim 1 to the patient.
32 . A method of treating obesity in a patient in need thereof, the method comprising administering the controlled release tablet of claim 1 to the patient.
33 . A method of treating alcohol, cocaine and/or tobacco dependence in a patient in need thereof, the method comprising administering the controlled release tablet of claim 1 to the patient.
34 . A method of treating bipolar disorder in a patient in need thereof, the method comprising administering the controlled release tablet of claim 1 to the patient.